BioCentury | Jul 5, 2010
Company News

DiaMedica, Sanomune deal

...DiaMedica completed its previously announced acquisition of Sanomune in a stock deal valued at C$5.4 million...
...day before the deal closed (see BioCentury, Dec. 7, 2009). DiaMedica Inc. (TSX-V:DMA), Winnipeg, Manitoba Sanomune Inc....
BioCentury | Dec 7, 2009
Company News

DiaMedica, Sanomune deal

...DiaMedica signed a non-binding letter of intent to acquire Sanomune in a stock deal. Sanomune will...
...on DiaMedica's close of C$0.62 on Nov. 30, the day before the deal was announced. Sanomune's...
...on the deal, which is expected to close in January. DiaMedica Inc. (TSX-V:DMA), Winnipeg, Manitoba Sanomune Inc....
BioCentury | Mar 9, 2009
Company News

Sanomune, HealthPartners Research Foundation deal

...The foundation granted Sanomune exclusive, worldwide rights to deferoxamine ( SAN-121 ), a nasally-delivered iron chelator...
...treat Alzheimer's disease. Sanomune expects to begin Phase I testing of the compound in 2010. Sanomune...
...a preclinical nasally-delivered repurposed biologic targeting amyloid-beta and tau protein. Financial terms were not disclosed. Sanomune Inc....
Items per page:
1 - 3 of 3
BioCentury | Jul 5, 2010
Company News

DiaMedica, Sanomune deal

...DiaMedica completed its previously announced acquisition of Sanomune in a stock deal valued at C$5.4 million...
...day before the deal closed (see BioCentury, Dec. 7, 2009). DiaMedica Inc. (TSX-V:DMA), Winnipeg, Manitoba Sanomune Inc....
BioCentury | Dec 7, 2009
Company News

DiaMedica, Sanomune deal

...DiaMedica signed a non-binding letter of intent to acquire Sanomune in a stock deal. Sanomune will...
...on DiaMedica's close of C$0.62 on Nov. 30, the day before the deal was announced. Sanomune's...
...on the deal, which is expected to close in January. DiaMedica Inc. (TSX-V:DMA), Winnipeg, Manitoba Sanomune Inc....
BioCentury | Mar 9, 2009
Company News

Sanomune, HealthPartners Research Foundation deal

...The foundation granted Sanomune exclusive, worldwide rights to deferoxamine ( SAN-121 ), a nasally-delivered iron chelator...
...treat Alzheimer's disease. Sanomune expects to begin Phase I testing of the compound in 2010. Sanomune...
...a preclinical nasally-delivered repurposed biologic targeting amyloid-beta and tau protein. Financial terms were not disclosed. Sanomune Inc....
Items per page:
1 - 3 of 3